Doug Ingram, CEO of Sarepta Therapeutics, will step down at the end of the year after nearly a decade leading the company. Ingram announced his decision during Sarepta’s fourth quarter earnings report, citing personal reasons related to his family.
“As you know, in late 2024 we entered into a partnership with Arrowhead, and we gained access to a number of very promising therapies, including SRP-1003, for a devastating disease, DM-1,” Ingram said. “Well, subsequent to that partnership in a fairly shocking and certainly ironic twist of fate, my personal commitment to muscular dystrophy is deepened, as two members of my immediate family have been diagnosed now with myotonic dystrophy, DM-1.”
Ingram explained that when he took on the role in 2017 he did not have a personal connection to muscular dystrophy. “Through my work at Sarepta, I have developed a zealous passion for our quest to improve the lives of those living with muscular dystrophy. I doubt anyone who knows me would disagree with that.”
He also mentioned that his responsibilities as CEO required him to spend extended periods in Boston and Cambridge while his family remained in California. The recent diagnoses within his family led him to prioritize commitments at home.
Sarepta’s board has begun searching for Ingram’s successor.
During his tenure, Ingram oversaw four drug approvals targeting Duchenne muscular dystrophy (DMD), including Elevidys—the first gene therapy approved for this condition. The company faced challenges such as mixed clinical trial results and difficult regulatory reviews but managed to secure FDA approvals for its treatments. These drugs provided new options for patients affected by DMD.
Last year was particularly challenging for Sarepta when safety concerns linked Elevidys and an experimental treatment to several patient deaths. This led to public disputes with the FDA over continued access to these therapies.
Ingram recognized these difficulties in his remarks: “We set audacious goals for ourselves, chief among them, the goal of lessening the burden and extending the lives of boys and young men with [DMD]. Along the way, as you all know, we solved many thorny scientific and technical problems, even as we faced and overcame many exogenous and extraordinary obstacles—challenges that would have undone a less committed, less creative, less resilient organization.”
He emphasized progress made under his leadership: “The work that Sarepta has done in DMD, with thousands of patients benefiting, would have been unimaginable a decade ago.” However, he also noted there is more work ahead: “This decision was a deeply difficult one for me as this is the most meaningful and rewarding role that one could imagine, and we stand at one of the most exciting moments in our entire history.”
